Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression

We endeavored to evaluate the efficacy of Lurasidone at doses of 40-160 mg per day on symptoms of schizophrenia associated with symptoms of depression in real clinical practice in a Russian patient population. One hundred sixty eight patients aged 18-65 years old, who at the time of the start of the...

Full description

Saved in:

Bibliographic Details
Published in:	Consortium psychiatricum (English ed. Online) Vol. 3; no. 3; pp. 56 - 72
Main Authors:	Reznik, Aleksandr, Syunyakov, Timur, Akhmerova, Inessa, Butylin, Daniil, Vasilenko, Anastasia, Gvozdetckii, Anton, Gizatullin, Tagir, Gilmanshina, Galina, Golosov, Egor, Kolchev, Sergey, Linova, Lidiya, Miron, Daniil, Mudrak, Aleksandr, Oleichik, Igor, Sizov, Stepan, Tarakanova, Elena, Chesnokova, Olga
Format:	Journal Article
Language:	English
Published:	Russia (Federation) Eco-Vector 2022
Subjects:	depression exacerbation of schizophrenia lurasidone psychopharmacotherapy schizophrenia second-generation antipsychotic lurasidone second-generation antipsychotic depression schizophrenia psychopharmacotherapy exacerbation of schizophrenia
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We endeavored to evaluate the efficacy of Lurasidone at doses of 40-160 mg per day on symptoms of schizophrenia associated with symptoms of depression in real clinical practice in a Russian patient population. One hundred sixty eight patients aged 18-65 years old, who at the time of the start of the observation were being treated in a hospital or day hospital due to an exacerbation of paranoid schizophrenia accompanied by symptoms of depression, were prescribed lurasidone. Treatment with lurasidone and other concomitant drugs, their prescription, withdrawal, selection, and dose modifications were determined based on the indications for the use of those drugs and the recommended doses in the instructions, clinical need, and patient interests, rather than by the goals of the study. During the observation period, the severity of depressive symptoms according to the Calgary Depression Scale (CDSS) and that of psychotic symptoms according to the Positive and Negative Syndrome Scale (PANSS) were assessed six times (before the start of treatment and then on the 4 , 7 , 14 , 28 , and 42 days). A statistically significant reduction in the severity of the symptoms was observed with the use of lurasidone in doses ranging from 40 mg to 160 mg per day. The fastest and most significant ( <0.001) reductions in the total PANSS and CDSS scores were observed with lurasidone 120 mg. A somewhat lower efficacy of lurasidone was observed at a dose of 160 mg. The largest reductions in the total PANSS and CDSS scores with lurasidone 120 mg were associated with the highest survival rate and the longest median time from treatment initiation to discontinuation or follow-up. The most commonly reported side effects with lurasidone in this study (nausea, akathisia, tremor and drowsiness) were consistent with the known safety profile of the drug. Adverse events in most cases were assessed as mild, or occasionally moderate. A six-week prospective observational study of the real-world clinical effectiveness of lurasidone in doses ranging from 40 mg to 160 mg per day established statistically and clinically significant improvements in both psychotic and depressive symptoms in patients with acute exacerbation of schizophrenia and associated symptoms of depression.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Daniil Yurievich Butylin, PhD, Pavlov First State Medical University of St. Petersburg; ORCID: https://orcid.org/0000-0001-7055-0065 Anton Nikolaevich Gvozdetckii, PhD, Chair of Psychiatry and Addiction Medicine North-Western State Medical University named after I.I. Mechnikov; ORCID: https://orcid.org/0000-0001-8045-1220 Tagir Rafailovich Gizatullin, Dr. of Sci. (Med.), Department of General Psychology, Bashkir State University; ORCID: https://orcid.org/0000-0002-1075-5648 Egor Aleksandrovich Golosov, Head of the Department, Psychiatric Hospital No. 1 named after P.P. Kaschenko; ORCID: https://orcid.org/0000-0003-4548-8225 Alexander Vladimirovich Mudrak, MD, psychiatrist, Mental-health Clinic No. 1 Named after N.A. Alexeev; ORCID: https://orcid.org/0000-0003-1315-516X Galina Vadimovna Gilmanshina, MD, Head of the Department of Internal Quality Control and Safety of Medical Activities, Republican Clinical Psychiatric Hospital of the Republic of Bashkortostan; ORCID: https://orcid.org/0000-0002-9755-8750 Stepan Vladimirovich Sizov, researcher, Department of Endogenous Mental Disorders and Affective Conditions, Mental Health Research Center; ORCID: https://orcid.org/0000-0002-8213-5122 Daniil Vasilievich Miron, MD, psychiatrist, intensive care unit for psychiatric care, City Psychiatric Hospital No. 6 (a hospital with a dispensary); ORCID: https://orcid.org/0000-0003-4675-5743 Igor Valentinovich Oleichik, MD, PhD, Dr. Sci. (Med.), principal researcher, Department of Endogenous Mental Disorders and Affective Conditions, Mental Health Research Center; ORCID: https://orcid.org/0000-0002-8344-0620 Sergey Aleksandrovich Kolchev, PhD, Chair of Psychiatry and Addiction Medicine, North-Western State Medical University named after I.I. Mechnikov; ORCID: https://orcid.org/0000-0002-9108-2317 E-mail: a.m.reznik1969@gmail.com Elena Aleksandrovna Tarakanova, MD, PhD, Dr. Sci. (Med.), The Volgograd Medical State University; ORCID: https://orcid.org/0000-0002-8725-522X Olga Ivanovna Chesnokova, MD, City Psychiatric Hospital No. 6 (a hospital with a dispensary), Psychiatric Hospital no. 1 Named after N.A. Alexeev of the Department of Health of Moscow; ORCID: https://orcid.org/0000-0002-5993-6626 Information about the authors: *Aleksandr Mikhailovich Reznik, MD, PhD, Assistant Professor, psychiatrist, Medical Institute of Continuing Education of Moscow State University of Food Production; ORCID: https://orcid.org/0000-0002-7076-5901, e-Library SPIN-code: 4955-8297 Inessa Yurievna Akhmerova, PhD, Department of General Psychology, Bashkir State University, Republican Clinical Psychiatric Hospital of the Republic of Bashkortostan; ORCID: https://orcid.org/0000-0001-5720-1610 Anastasia Olegovna Vasilenko, MD, PhD; Medical Center “Moy doctor”; ORCID: https://orcid.org/0000-0001-6103-8529 Timur Sergeevich Syunyakov, MD, PhD, Senior researcher, Research Zakusov Institute of Pharmacology, Moscow, Russia; Mental-health Clinic No. 1 named after N.A. Alexeev; ORCID: https://orcid.org/0000-0002-4334-1601, e-Library SPIN-code: 7629-5309 Lidiya Pavlovna Linova, MD, psychiatrist, Psychiatric Hospital No. 1 named after P.P. Kaschenko; ORCID: https://orcid.org/0000-0003-2712-3724
ISSN:	2712-7672 2713-2919 2713-2919
DOI:	10.17816/CP172